Ospemifene is the first oral and non-hormonal treatment for moderate or severe vulvo-vaginal atrophy (VVA) in postmenopausal women who are not candidates to treatment with local oestrogens. Its effects are mediated though the regeneration of the proportion of superficial and intermediate cells of the vagina, improving menopausal symptomatology such as dryness and dyspareunia.
Only two studies to date have directly compared brain activation patterns in women with normal sexual function with women complaining with hypoactive sexual desire disorder. Arnow et al. demonstrated that women with normal sexual function showed brain activations in multiple regions different from women with FSIAD. When comparing the two groups, women with normal sexual function showed greater activation of the bilateral entorhinal cortex while women with FSIAD exhibited greater activation of the medial frontal gyrus, right inferior frontal gyrus, and bilateral putamen. The medial frontal gyrus activation has been associated with self-monitoring; thus, it is possible that women with FSIAD allocate more attention to monitoring their response, which may be inhibitory to sexual functioning. The other study was done by Woodard and colleges showing that women with normal sexual function showed significantly differences on cerebral activation in comparison with women with FSIAD.
These differences observed in women with FSIAD could suggest that they may have alterations in activation of limbic and cortical structures responsible for acquiring, encoding, and retrieving memory, the processing and memory of emotional reactions, and areas responsible for heightened attention to one's own physical state.
For this reason the authors believe that it is essential to determine if the effect of ospemifene on the improvement on sexual function is due to the improvement on the vagina tract or due to its effect on brain function.

Start Date01 Nov 2021

Sponsor / Collaborator

Hospital Clínic de Barcelona

NCT03018106

/ TerminatedPhase 4IIT

Ospemifene Versus Conjugated Estrogens in the Treatment of Postmenopausal Sexual Dysfunction

Vulvovaginal atrophy (VVA) is a condition that impacts up to 60% of the growing postmenopausal female population, and the most common symptom is dyspareunia. Vaginal estrogen is the most common treatment for VVA, but it only marginally improves overall sexual function, and many women and clinicians avoid using it because of the risks of exogenous estrogen use during menopause. Ospemifene is a non-estrogen selective estrogen receptor modulator (SERM) that is FDA-approved for treating dyspareunia related to VVA, and has shown superb improvements in overall sexual health. 104 women will be randomized to receive 12 weeks of 60mg oral ospemifene, taken daily, or 12 weeks of 0.5mg vaginal conjugated estrogens, which is placed vaginally twice per week. The improvements in sexual health and VVA symptom severity will be compared in each group. This study will help determine if ospemifene is a better treatment medication than conjugated estrogens.

Start Date30 Jun 2017

Sponsor / Collaborator

Emory University

NCT02638337

/ CompletedPhase 3

A Phase 3, Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Efficacy and Safety of Ospemifene in Patients With Moderate to Severe Vaginal Dryness, a Symptom of Vulvo-vaginal Atrophy (VVA) Due to Menopause

The objective of this study is to evaluate the efficacy and safety of ospemifene 60 mg once daily (QD) compared with placebo in treatment of vulvo-vaginal atrophy (VVA) due to menopause in women with moderate to severe vaginal dryness as the most bothersome symptom (MBS) of VVA.

Start Date26 Jan 2016

Sponsor / Collaborator

Shionogi, Inc.

100 Clinical Results associated with Ospemifene

100 Translational Medicine associated with Ospemifene

100 Patents (Medical) associated with Ospemifene

249

Literatures (Medical) associated with Ospemifene

01 Jun 2026·JOURNAL OF PHARMACEUTICAL SCIENCES

A computationally informed framework for lipid-based formulation developability: Integrating predictive models with case studies

Article

Author: Griffin, Brendan T ; Ryan, Callum D ; O'Shea, Joseph P

The increasing prevalence of poorly water-soluble drugs (PWSDs) in development pipelines has intensified the need for bio-enabling strategies such as lipid-based formulations (LBFs). However, formulation selection for optimal bioavailability often relies on empirical, resource-intensive approaches. This study introduces a computationally informed developability framework that integrates predictive models to streamline LBF development. The framework combines in silico tools for assessing key determinants of LBF suitability-including predictions of food effect, lipid solubility, and biopharmaceutical dose number (Do)-with tailored strategies such as lipophilic salt synthesis for challenging molecules. A database of >200 FDA-approved oral drugs (2010-2023) was screened through the computational framework, and four case studies (dapagliflozin, mavacamten, ospemifene, flibanserin) illustrate the framework's ability to classify risk and guide formulation decisions. Predictions identified low-risk candidates for or type-I LBFs, highlighted medium-risk molecules requiring type-IIIa formulations, and demonstrated the utility of lipophilic salts for drugs which are high-risk with respect to dose-loading and dose number limitations. This integrated approach enables rapid, data-driven formulation decisions, reducing reliance on trial-and-error methods and supporting early-stage development of PWSDs. By coupling computational predictions with targeted experimental validation, the framework offers a practical roadmap for accelerating LBF adoption and improving R&D efficiency.

01 Mar 2026·DRUGS & AGING

Treating Genitourinary Syndrome of Menopause in Postmenopausal Women with a History of Breast Cancer

Review

Author: Kling, Juliana M ; Ferguson, Dewonna ; Pederson, Holly

Genitourinary syndrome of menopause (GSM) remains widely underdiagnosed and undertreated. It affects up to 60% of breast cancer survivors, is often worsened by oncologic treatments and can progress with age, all leading to diminishing quality of life, particularly in older women. A stepwise, symptom-driven treatment model is recommended-beginning with non-hormonal options and advancing to local vaginal therapies or ospemifene when appropriate. Treatment decisions should be tailored to cancer subtype, receptor status, prior therapies, and time since diagnosis, while also considering symptom burden and patient preferences. Local estrogen is generally safer in tamoxifen users, but caution is warranted with aromatase inhibitors due to potential systemic absorption. In patients with estrogen receptor-negative disease, local hormone use may be considered but requires careful risk-benefit evaluation and shared decision making is essential. Until long-term safety data emerge, management should remain individualized, evidence-based, and multidisciplinary.

01 Feb 2026·INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER

Hormone replacement therapy in gynecologic cancer: oncologic safety and alternative therapies

Review

Author: Montero-Macias, Rosa ; Palasz, Natalia Anna ; Ramirez, Pedro T ; Luzarraga Aznar, Ana ; Elyashiv, Osnat ; Pavone, Matteo ; Jayraj, Aarthi S ; Hsu, Heng-Cheng ; Canturk, Muhterem Melis ; Dababou, Susan

Recent advances in surgery and new therapies have greatly improved outcomes for gynecologic cancers, leading to more long-term survivors and a stronger focus on quality of life. Treatments such as surgery, radiation, and chemotherapy often cause iatrogenic menopause, leading to reduced quality of life and long-term health consequences. Hormone replacement therapy is the most effective option for managing menopausal symptoms. However, its use in patients with gynecologic cancer remains controversial because of concerns regarding oncologic safety. We conducted a comprehensive literature review evaluating the safety of hormone replacement therapy in survivors of endometrial, ovarian, cervical, vulvar, and vaginal cancers and uterine sarcomas, as well as in patients with hereditary cancer syndromes. Systemic hormone replacement therapy is safe in women with low-risk, early-stage endometrial cancer, most ovarian cancer sub-types, cervical cancer regardless of histology, and vulvar or vaginal cancers. However, contra-indications exist in specific scenarios such as advanced or non-endometrioid endometrial cancer, uterine sarcomas, and certain ovarian cancer sub-types (granulosa-cell tumors). In these cases, both non-systemic hormonal and non-hormonal alternatives have shown efficacy in managing menopausal symptoms. Hormonal therapies for genitourinary syndrome of menopause, including vaginal estrogens, ospemifene, and vaginal dehydroepiandrosterone, have demonstrated efficacy in relieving symptoms and improving urogenital health. Non-hormonal approaches, such as vaginal moisturizers, lubricants, and vaginal laser therapy, can also provide symptom relief. Non-hormonal therapies proven effective for managing vasomotor symptoms and sleep disturbances include cognitive behavioral therapy, clinical hypnosis, gabapentin, fezolinetant, and selective serotonin or serotonin-norepinephrine re-uptake inhibitors. Personalized treatment decisions should be guided by cancer type, recurrence risk, patient preferences, and quality-of-life considerations. It is essential to balance oncologic safety with symptom relief and long-term health outcomes in this growing population of cancer survivors.

News (Medical) associated with Ospemifene

13 May 2025

·www.prnewswire.com

Duchesnay USA and MyMenopauseRx join in a partnership to offer expert consultations for menopausal women

PRINCETON, NJ, May 13, 2025 /PRNewswire/ - Duchesnay USA, a specialty pharmaceutical company dedicated to women's health and part of Duchesnay Pharmaceutical Group (DPG), is pleased to announce a strategic partnership with MyMenopauseRx, a virtual doctor's office dedicated to offering high-quality specialists consultations that expand access to care for women transitioning through menopause. Continue Reading Duchesnay USA and MyMenopauseRx join in a partnership (CNW Group/Duchesnay USA) This collaboration aims to bridge the healthcare gap that exists in this often overlooked area. Through this initiative, women will have insurance-covered access to board-certified menopause specialists at any time from the 26 states MyMenopauseRx currently serves, with more states coming soon. "With women's well-being at the heart of our philosophy, we, at Duchesnay USA, believe that menopausal women deserve the same level of attention, care, and innovation as any other patient population," said Tanya Carro, Executive Vice President, U.S. Entities. "This partnership combines Duchesnay USA's commitment to research and innovation with MyMenopauseRx's deep expertise in the treatment of menopausal symptoms, ensuring that more women can rely on expert care when and where they need it." Founded by Dr. Barbra Hanna, a board-certified gynecologist and Menopause Society Certified Practitioner, MyMenopauseRx offers FDA-approved therapies and board-certified guidance backed by science through telehealth visits that are covered by most major health insurance plans. "Navigating menopause can be incredibly challenging because it's often misunderstood and under-discussed. Many women face stigma when speaking openly about their symptoms, struggle to find clinicians with specialized training, and are left without clear guidance on evidence-based treatments," said Dr. Barbra Hanna, founder of MyMenopauseRx. "By partnering with Duchesnay USA, we aim to empower women with the knowledge and expert care to transition this stage of life with confidence." MyMenopauseRx menopause specialist consultations are available through the Osphena website. IMPORTANT SAFETY INFORMATION Indication: What is Osphena® (ospemifene)? Osphena is a prescription oral pill that treats moderate to severe painful intercourse and/or moderate to severe vaginal dryness, both symptoms of changes in your vagina, due to menopause. BOXED WARNING: ENDOMETRIAL CANCER AND CARDIOVASCULAR DISORDERS Osphena® works like estrogen in the lining of the uterus (endometrium), but can work differently in other parts of the body. Taking estrogen alone or Osphena® may increase your chance for getting cancer of the lining of the uterus. Vaginal bleeding after menopause may be a warning sign of cancer of the lining of the uterus. Your healthcare provider should check any unusual vaginal bleeding to find out the cause, so tell him or her right away if this happens while you are using Osphena® . Osphena® may increase your chances of having a stroke or blood clots. You and your healthcare provider should talk regularly about whether you still need treatment with Osphena® . Most Important Information you should know about Osphena® Call your healthcare provider right away if you have unusual vaginal bleeding, changes in vision or speech, sudden new severe headaches, and pains in your chest or legs with or without shortness of breath, weakness and fatigue. Who should not take OSPHENA? Osphena® should not be used if you have unusual vaginal bleeding, have had certain types of cancers, have or have had blood clots, had a stroke or heart attack, have severe liver problems, are allergic to Osphena® or any of its ingredients, or think you may be pregnant. Tell your healthcare provider if you are going to have surgery or will be on bed rest. POSSIBLE SIDE EFFECTS Serious but less common side effects can include: stroke, blood clots and cancer of the lining of the uterus. Less serious, but common side effects include: hot flushes or flashes, vaginal discharge, muscle spasms, headache, excessive sweating (hyperhidrosis), heavy vaginal bleeding (vaginal hemorrhage), night sweats Tell your healthcare provider about all of the medicines and supplements you take, as some medicines may affect how Osphena® works. Osphena® may also affect how other medicines work. Duchesnay USA encourages you to report negative side effects of prescription drugs to the FDA. Visit or call 1-800-FDA-1088. Please read accompanying Patient Information for Osphena®(ospemifene) tablets, including Boxed Warning in the U.S. Full Prescribing Information. ABOUT DUCHESNAY USA Duchesnay USA is a specialty pharmaceutical company with a long-standing commitment to women's health. The company focuses on filling the void in terms of scientific research and education and on developing pharmacological solutions that are safe and effective for use during pregnancy and breastfeeding. Duchesnay USA also commercializes a broad portfolio of products to offer safe and effective therapeutic options that meet the health and quality of life needs of women and their family members at various stages of their lives. For more information, please visit: . Follow us on LinkedIn. ABOUT DUCHESNAY PHARMACEUTICAL GROUP Duchesnay Pharmaceutical Group (DPG), with its affiliated companies, is headquartered in Blainville, Quebec. The Group consists of six pharmaceutical companies to meet the needs of patients in Canada, the U.S. and abroad. The companies are Duchesnay (Canada) and Duchesnay USA, both dedicated to women's health; Medunik Canada and Medunik USA, which provide treatments for rare and debilitating diseases; and Analog Pharma Canada and Analog Pharma, specializing in orphan generic medications. From its state-of-the-art manufacturing plant, DPG exports its innovative treatments to more than 50 countries. DPG is one of the eight companies across the country chosen to participate in the Government of Canada's Global Hypergrowth Project. This appointment offers exclusive and personalized support for at least two years, in order to accelerate its growth to become an anchor firm in the Canadian economy. DPG is the winner of the 2024 Life Sciences Innovation Award by ADRIQ, the Association for the Development of Research and Innovation of Quebec, which recognizes DPG's healthy workplace culture and commitment to pharmaceutical innovation, while DPG president Éric Gervais is the recipient of the 2024 Bernard-Landry Award by ADRIQ which acknowledges his impactful leadership on Quebec's research and innovation ecosystem. DPG, through its proprietary research and development, and through exclusive partnerships, offers innovative treatments for a variety of medical conditions in women's health, urology, oncology and for rare diseases, plus lower-cost generic medications. DPG recognizes the dedication and professionalism of its employees and promotes a positive culture and flexible work environment. It is deeply committed to environmental responsibility and to giving back to the community through the support of various charitable organizations. For more information, please visit . Follow us on LinkedIn. About MyMenopauseRx MyMenopauseRx was founded by Dr. Barbra Hanna, DO, FACOG, MSCP, with the mission to empower women with access to high-quality virtual menopause care, covered by health insurance, so they can live their best lives. As a virtual doctor's office and telemedicine platform, MyMenopauseRx specializes in personalized care for women navigating perimenopause and menopause. Virtual appointments with menopause society-certified practitioners are available in an increasing number of states across the U.S., making expert care more accessible than ever. For more information, visit . SOURCE Duchesnay USA WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

10 Sep 2024

·www.drugs.com

Review Weighs Treatments for Genitourinary Symptoms of Menopause

TUESDAY, Sept. 10, 2024 -- Vaginal estrogen, vaginal dehydroepiandrosterone (DHEA), oral ospemifene, and vaginal moisturizers may be beneficial for some genitourinary symptoms of menopause (GSM), according to a review published online Sept. 10 in the Annals of Internal Medicine . Elisheva R. Danan, M.D., M.P.H., from the University of Minnesota in Minneapolis, and colleagues examined the effectiveness and harms of vaginal estrogen, nonestrogen hormone therapies, and vaginal moisturizers for treatment of GSM in a systematic review of randomized controlled trials (RCTs). A total of 46 RCTs assessing vaginal estrogen, nonestrogen hormones, vaginal moisturizers, or multiple interventions were identified from 11,993 citations. The researchers found that vaginal estrogen may improve vulvovaginal dryness, dyspareunia , the most bothersome symptom, and treatment satisfaction compared with placebo or no treatment. Vaginal DHEA may improve dryness, dyspareunia, and distress, bother, or interference from genitourinary symptoms compared with placebo; oral ospemifene may improve dryness, dyspareunia, and treatment satisfaction; and dryness may also be improved by vaginal moisturizers (all low certainty of evidence [COE]). No benefit or uncertain effects (low and very low COE, respectively) may be provided by vaginal testosterone, systemic DHEA, vaginal oxytocin, and oral raloxifene or bazedoxifene. Reporting was limited by studies of short duration that were insufficiently powered to assess infrequent serious harms. "Future studies would be strengthened by standard definitions of symptoms and uniform diagnostic criteria for GSM, a common set of validated outcome measures and reporting standards, and attention to clinically relevant patient populations and intervention comparisons," the authors write.

Clinical Result

21 Jun 2022

·www.biospace.com

Duchesnay announces the launch of Vablys® (dequalinium chloride vaginal tablets), an antiseptic and anti-infective treatment for bacterial vaginosis

BLAINVILLE, Quebec, June 21, 2022 (GLOBE NEWSWIRE) -- Duchesnay Inc., a pharmaceutical company specializing in women’s health and part of Duchesnay Pharmaceutical Group headquartered in Blainville, Quebec, is pleased to announce that it has launched its newest treatment, Vablys® (dequalinium chloride vaginal tablets). Vablys® is the first prescription antiseptic and anti-infective treatment for bacterial vaginosis in women under 55 years of age. With its multiple modes of action and anti-infective properties against a wide range of pathogens, a treatment course of Vablys® consists of one tablet inserted in the vagina at bedtime for six consecutive days. “Vablys® offers Canadian physicians and their patients the first gynecological anti infective and antiseptic prescription treatment option,” said Gino Henry, Senior Manager, Commercial Affairs, at Duchesnay. “We’re convinced that our product provides a new and effective way to treat this condition.” 1 Vablys® is the third new prescription treatment for Canadian women launched by Duchesnay in 2022, achieving an aggressive target set by the company’s new management team. The other two new treatments are the contraceptive Slynd® (drospirenone), a progestin-only pill (POP) which offers a 24-hour safe window for a missed pill, during which no other contraception is needed to prevent pregnancy, and Osphena® (ospemifene tablets), a selective estrogen receptor modulator (SERM) approved by Health Canada as a once-daily prescription treatment for postmenopausal women to treat vaginal dryness and painful intercourse. “Duchesnay is very proud to have achieved its ambitious target of bringing three new innovative prescription treatments to Canadian women in the first six months of 2022, a key element of our growth plans under our new management team,” said Dany Hallé, Vice-President, Commercial Affairs at Duchesnay. “All three new treatments address important needs for women at different stages of their lives and demonstrate concretely the commitment of Duchesnay to providing women’s health solutions. We look forward to continuing to do so.” The Health Canada-approved product monographs for Vablys®, Slynd® and Osphena® are available on the Duchesnay website at . They give contraindications, warnings, precautions, adverse reactions, interactions, dosing and conditions of clinical use. The product monographs are also available through the Duchesnay Medical Information Department, 1-888-666-0611 or medicalinfo@duchesnay.com. About bacterial vaginosis Bacterial vaginosis (BV) is an imbalance of the naturally-occurring, healthy bacteria found in the vagina or internal genitals. This imbalance can cause symptoms that may include more vaginal discharge than usual, a fish-like smell or irritation in the vaginal area2, though often symptoms are not noticed. According to the Public Health Agency of Canada, bacterial vaginosis is the most common cause of vaginal discharge in people of reproductive age. Bacterial vaginosis is not usually considered sexually transmitted, but it is associated with increased acquisition of human immunodeficiency virus (HIV), human papilloma virus (HPV) and Chlamydia trachomatis (CT).3 About Duchesnay Pharmaceutical Group Duchesnay Pharmaceutical Group, with its affiliated companies, is headquartered in Blainville, Quebec. The group consists of five pharmaceutical companies to meet the needs of patients in Canada, the U.S. and abroad. The companies are Duchesnay and Duchesnay USA, both dedicated to women's health; Médunik Canada and Medunik USA, which provide treatments for rare diseases; and Analog Pharma, an American generic drugs company, specializing in authorized generics and orphan drugs. From its state-of-the-art manufacturing plant, Duchesnay can export its innovative treatments to more than 50 countries. Duchesnay and Medunik, through their proprietary research and development, and through partnerships, offer innovative treatments for a variety of medical conditions in women's health, urology, oncology as well as for rare diseases. The group of companies recognizes the dedication and professionalism of its employees and promotes a positive culture and flexible work environment. It is deeply committed to environmental responsibility and giving back to the community through the support of various charitable organizations. For more information, please visit duchesnay.com, medunik.com and analogpharma.com. References Duchesnay Inc., Vablys® Product Monograph, September 2021. British Columbia Centre for Disease Control, Bacterial Vaginosis, Health Canada, STI-associated syndromes guide: Vaginitis, Public Health Importance, September 2021, Media contact: Email: info@duchesnay.com Telephone: (877) 833-7734 A photo accompanying this announcement is available at Vablys Vablys

Orphan DrugGeneric DrugAcquisition

100 Deals associated with Ospemifene

External Link

KEGG	Wiki	ATC	Drug Bank
D08958	Ospemifene	G03XC05	DB04938

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
vaginal mucosa dry	United States	Duchesnay, Inc.	25 Jan 2019
Vulvovaginal atrophy	European Union	Qualicaps Netherlands BV	14 Jan 2015
Vulvovaginal atrophy	Iceland	Qualicaps Netherlands BV	14 Jan 2015
Vulvovaginal atrophy	Liechtenstein	Qualicaps Netherlands BV	14 Jan 2015
Vulvovaginal atrophy	Norway	Qualicaps Netherlands BV	14 Jan 2015
Vulvovaginal atrophy	United Kingdom	Shionogi BV	14 Jan 2015
Dyspareunia	United States	Duchesnay, Inc.	26 Feb 2013

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Atrophy	Phase 3	-	Shionogi, Inc.	01 Jan 2006
Atrophy	Phase 3	-	QuatRx Pharmaceuticals Co.	01 Jan 2006

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02784613 (CTgov)	Phase 4	Vulvovaginal atrophy \| Dyspareunia	10	ospemifene	xndukrskyx(zdtuknulpc) = bdhgppmbax hmbuiurlxg (eifvnizxxp, biexlrlnnq - frnyetpjio) View more	-	02 Apr 2019
NCT02638337 (CTgov)	Phase 3	Vulvovaginal atrophy \| vaginal mucosa dry	631	Ospemifene (Ospemifene)	hdmhdkdkex(nfrpcfvmld) = tboaptgbli pdsagmklmk (heuthjhndd, 1.4) View more	-	02 Apr 2019
				Placebo (Placebo)	hdmhdkdkex(nfrpcfvmld) = rxyflanykq pdsagmklmk (heuthjhndd, 1.4) View more
NCT02638337 (Pubmed \| Menopause)	Phase 3	vaginal mucosa dry	631	Ospemifene 60mg	nekbjpoyjp(gzkcmlreaj) = uvrvmpezlw xgdmmvvhka (jnfkqrxffb ) View more	Positive	28 Jan 2019
				Placebo	nekbjpoyjp(gzkcmlreaj) = onopasvyag xgdmmvvhka (jnfkqrxffb ) View more
NCT03018106 (CTgov)	Phase 4	Sexual Dysfunction, Physiological \| Sexual Dysfunction \| Dyspareunia	1	Vaginal conjugated estrogens	pomvsdpavz = lnxvboysxt hbwntigrfb (qtovdhxjit, zwczqjffkj - uepisoyflg) View more	-	20 Dec 2017
NCT00729469 (CTgov)	Phase 3	Vulvovaginal atrophy \| vaginal mucosa dry \| Atrophy	919	Placebo (Subjects on Placebo)	wrvqxzfomj(awphxrduis) = zftrzelaxf azxvussuep (kgukmejybn, 29.97) View more	-	28 Jun 2013
				Ospemifene (Subjects on Ospemifene 60 mg/Day)	wrvqxzfomj(awphxrduis) = klbefriznj azxvussuep (kgukmejybn, 37.25) View more
NCT00276094 (CTgov)	Phase 3	Vulvovaginal atrophy \| Atrophy	826	Nonhormonal vaginal lubricant+Ospemifene 30 mg (Ospemifene 30 mg/Day and Nonhormonal Vaginal Lubricant)	epikuafsnr(ggkbesuhty) = smnqfkxhie ympgopxqve (ymqqzyvlcf, 0.929) View more	-	28 Jun 2013
				Nonhormonal vaginal lubricant+Ospemifene 60 mg (Ospemifene 60 mg/Day and Nonhormonal Vaginal Lubricant)	epikuafsnr(ggkbesuhty) = uvalrlcxbz ympgopxqve (ymqqzyvlcf, 1.025) View more
NCT00630539 (CTgov)	Phase 2	Vulvovaginal atrophy \| Atrophy	126	Placebo (Subjects on Placebo)	ffhlvoglls(vbmfwemksy) = wresjzsadi xquzxqpgms (mpsaxohvou, 30.2) View more	-	28 Jun 2013
				Ospemifene 5 mg (Subjects on Ospemifene 5 mg/Day)	ffhlvoglls(vbmfwemksy) = mqygurwriz xquzxqpgms (mpsaxohvou, 33.2) View more
NCT01586364 (CTgov)	Phase 3	Vulvovaginal atrophy \| Atrophy	301	Ospemifene	ndnrydirby = arcnueionq ffdgbwkeyl (pnzgcqqegt, ytatlacmui - wpyxkreyhx) View more	-	28 Jun 2013
NCT00566982 (CTgov)	Phase 3	Vulvovaginal atrophy \| Atrophy	426	Placebo (Subjects on Placebo (Baseline))	xnkygvkvjy(xjsvvxkbvx) = cbhgvwudjy cvpqvswzzc (dtszzqexgo, 27.86) View more	-	28 Jun 2013
				Ospemifene (Subjects on Ospemifene 60 mg/Day (Baseline))	xnkygvkvjy(xjsvvxkbvx) = vsojqefdgf cvpqvswzzc (dtszzqexgo, 41.96) View more
NCT01585558 (CTgov)	Phase 3	Vulvovaginal atrophy \| Atrophy	180	Ospemifene (Ospemifene 30 mg (Dose 1))	jhxneutxgy = cojvysmvcl cubeksrkrs (lqfwdofrcf, tklqcdapdd - onnthlctuc) View more	-	28 Jun 2013
				Ospemifene (Ospemifene 60 mg (Dose 2))	jhxneutxgy = ptswzcjuxy cubeksrkrs (lqfwdofrcf, qetdiykqpt - kkmkpdouwn) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis